What it sells
Rare Disease-Focused Care Delivery and Evidence Generation Platform
Business model breakdown
Buyer: who owns the budget?
UnverifiedRare disease programs: pharma sponsors and hemophilia/sickle cell treatment centers (inferred; HCP dashboard and demo CTA).
Workflow: what inputs become what output?
Patients log in the Microhealth app (bleeding disorders, sickle cell disease, PLGD) and clinicians monitor them in real time via an HCP dashboard between visits.
Economics: what it saves and how it charges
Mission statement cites economic value alongside outcomes and research; commercial model not stated.
Distribution: how it reaches customers
Book a demo; compliance (SOC 2 Type II, HIPAA, ISO 13485, CE mark) is highlighted for enterprise buyers.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2015 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.